EDGAR Filing Documents for 0001193125-17-250556

Form 8-K - Current report:

SEC Accession No. 0001193125-17-250556

Filing Date

2017-08-08

Accepted

2017-08-08 06:10:58

Documents

Period of Report

2017-08-07

Items

Item 1.01: Entry into a Material Definitive Agreement
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq	Description	Document	Type	Size
1	8-K	d434413d8k.htm	8-K	50814
2	EX-2.1	d434413dex21.htm	EX-2.1	669580
3	EX-10.1	d434413dex101.htm	EX-10.1	48963
4	EX-10.2	d434413dex102.htm	EX-10.2	44145
5	EX-10.3	d434413dex103.htm	EX-10.3	19348
6	EX-99.1	d434413dex991.htm	EX-99.1	26554
7	GRAPHIC	g434413g0808081102232.jpg	GRAPHIC	2608
8	GRAPHIC	g434413g0808081102357.jpg	GRAPHIC	4096
	Complete submission text file	0001193125-17-250556.txt		870645

Mailing Address 4640 SW MACADAM AVENUE SUITE 270 PORTLAND OR 97239

Business Address 4640 SW MACADAM AVENUE SUITE 270 PORTLAND OR 97239 855 855 GALE

Galena Biopharma, Inc. (Filer) CIK: 0001390478 (see all company filings)